Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans
TheFly reported on April 9 that Maxim Group downgraded RVPH from Buy to Hold.
Reviva Pharmaceuticals Holdings Inc. (RVPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 793,948 | $579,344 | 0% | |
| 2. | Highbridge Capital Management Glenn Russell Dubin | 762,236 | $556,204 | 0.02% | |
| 3. | Armistice Capital Steven Boyd | 592,079 | $432,040 | 0.01% | |
| 4. | Renaissance Technologies Jim Simons | 43,002 | $31,379 | 0% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 10,715 | $7,819 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.69 | 3,000 | $14,070.00 | 43,547 | 2022-11-18 | Filing | |
| $1.66 | 50,000 | $83,000.00 | 100,000 | 2022-09-30 | Filing | |
| $1.21 | 50,000 | $60,670.00 | 50,000 | 2022-06-30 | Filing | |
| $3.75 | 399,000 | $1,496,250.00 | 399,000 | 2021-06-01 | Filing | |
| $3.75 | 931,000 | $3,491,250.00 | 931,000 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.88 | 367,000 | $3,992,960.00 | 0 | 2020-12-08 | Filing | |
| $11.51 | 50,000 | $575,500.00 | 710,000 | 2020-12-07 | Filing | |
| $11.00 | 261 | $2,871.00 | 606,360 | 2020-12-02 | Filing | |
| $11.00 | 5,362 | $58,982.00 | 606,621 | 2020-12-01 | Filing | |
| $10.90 | 5,969 | $65,062.10 | 611,983 | 2020-11-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,399,500 | $1,021,215 | 0% | |
| 2. | 502,300 | $366,679 | 0% | |
| 3. | 117,568 | $85,825 | 0% | |
| 4. | 90,772 | $66,218 | 0.01% | |
| 5. | 72,992 | $53,265 | 0% |
News See All
8 Oversold Biotech Stocks to Invest In Now
On February 5, J.P. Morgan revealed major themes that are expected to affect healthcare in 2026, emphasizing a resurgence of interest in the biopharma sector.
Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split
As of March 19, 2026, 83% of covering analysts maintain bullish ratings for Reviva Pharmaceuticals Holdings, Inc.
Top 10 Stocks Under $5 That Could Triple
At one end of the spectrum, until a few weeks ago, there was optimism about the broader market's performance this year.
Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026
However, at the same time, Reviva Pharmaceuticals Holdings, Inc.
10 Stocks Under $1 That Will Explode
U.S. equity markets are beginning their 2026 journey without taking a major break from existing trends, according to Morgan Stanley CIO and chief U.S.
15 Best-Performing Stocks in the Last 12 Months
The US stock market has been performing unusually well in 2023. The most recent catalyst came after the Federal Reserve’s fight against inflation started signs of bearing fruit.
Is Reviva Pharmaceuticals Holdings, Inc. (RVPH) A Good Stock To Buy?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their...